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ABSTRACT
Antisense oligodeoxynucleotides (oligos) are widely
used for functional studies of both prokaryotic and
eukaryotic genes. However, the identification of
effective target sites is a major issue in antisense
applications. Here, we study a number of thermo-
dynamic and structural parameters that may affect
the potency of antisense inhibition. We develop a
cell-free assay for rapid oligo screening. This assay
is used for measuring the expression of Escherichia
coli lacZ, the antisense target for experimental
testing and validation. Based on a training set of
18 oligos, we found that structural accessibility
predicted by local folding of the target mRNA is the
most important predictor for antisense activity. This
finding was further confirmed by a direct validation
study. In this study, a set of 10 oligos was designed
to target accessible sites, and another set of 10
oligos was selected to target inaccessible sites.
Seven of the 10 oligos for accessible sites were
found to be effective (.50% inhibition), but none of
the oligos for inaccessible sites was effective.
The difference in the antisense activity between
the two sets of oligos was statistically significant.
We also found that the predictability of antisense
activity by target accessibility was greatly improved
for oligos targeted to the regions upstream of the
end of the active domain for b-galactosidase,
the protein encoded by lacZ. The combination of
the structure-based antisense design and extension
of the lacZ assay to include gene fusions will be
applicable to high-throughput gene functional
screening, and to the identification of new drug
targets in pathogenic microbes. Design tools are
available through the Sfold Web server at http://
sfold.wadsworth.org.
INTRODUCTION
Antisense oligodeoxynucleotides (oligos), usually  20 nt in
length, can modulate gene expression by hybridizing with
cognate RNAs at complementary target sites (1). The poten-
tial of antisense oligos for fast and speciﬁc gene inhibition
makes them useful tools for functional genomics studies
and drug target validation (2–4). The promise of antisense
oligos for therapeutic development has also been demon-
strated (5–8).
It has been shown that usually only a small proportion
of antisense oligos are functional and even fewer oligos
are potent (9–11). The identiﬁcation of effective target sites
is a major issue in antisense applications. Experimental
approaches to addressing this problem include the ‘gene
walk’ approach, use of random or semi-random oligo
libraries, and use of combinatorial oligonucleotide arrays
(12–15). For example, the ‘gene walk’ approach empirically
tests a large number of oligos targeted to various regions of
the target mRNA, with a typical low success rate of 2–5%
(16). These experimental approaches can identify effective
target sites; however, they are time-consuming and costly,
and are not easily adaptable for application to a large number
of targets.
A number of sequence motifs have been reported to be
correlated with antisense activity (17,18). However, such
motif correlations are not supported by results from other
studies (19–21). In addition, the GC content has been found
to be a poor predictor of hybridization intensity (22). The
essential step of the antisense process is the hybridization
between the antisense oligo and its target mRNA; this can
be simply viewed as a two-step process of nucleation at an
accessible (single-stranded, unstructured) site and elongation
by a ‘zippering’ process (15). There is compelling experi-
mental evidence that the likelihood of successful hybridiza-
tion is greatly inﬂuenced by secondary structural features of
the target RNA (15,23–25).
Computational approaches to target-site selection are usu-
ally based on identiﬁcation of accessible regions via predicted
secondary structure of the target RNA. The mfold software
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with limited success (14,16). For RNA folding prediction,
the mfold software is based on free energy minimization.
In a radical departure from free energy minimization, a statis-
tical sampling approach to RNA folding prediction and
antisense application has demonstrated promise and advan-
tages (3,29–31). In comparisons with minimum free energy
(MFE) predictions, this method has been shown to make
better predictions of alternative mRNA structures (30) and
antisense efﬁcacy (3), and it enables an improved representa-
tion of the probable population of mRNA structures (32).
This approach is the focus of two recent reviews on RNA
secondary structure prediction algorithms (31,33). In this
study, we further explore the value of the structure sampling
algorithm for the rational design of antisense oligos using a
cell-free assay system that we developed for rapid oligo
screening. This assay system is used to measure expression
of the Escherichia coli lacZ gene, the antisense target for
experimental testing and validation. Based on testing results
for a training set and two test sets of oligos, we found that
the structural accessibility of the target is the most important
predictor for antisense activity. This ﬁnding suggests a
structure-based rational antisense design for prokaryotic
applications.
MATERIALS AND METHODS
In vitro gene expression assay
The lacZ gene was expressed by in vitro transcription/
translation from a fused nfo promoter in pRPC179 (provided
by R. Cunningham, University at Albany, Albany, NY), using
the E.coli S30 Extract System for Circular DNA (Promega).
pRPC179 includes the promoter sequence of nfo and the
beginning 144 nt of its open reading frame (ORF), which
was fused to lacZ ORF at 19 nt, with a 18 nt linker sequence.
Thus, b-galactosidase was expressed as a fusion protein that
includes 48 amino acids from the N-terminal of EndoIV
protein encoded by nfo and 6 amino acids encoded by the
linker sequence. In vitro transcription/translation reactions
were performed for 2 h at 37 C according to Promega’s
recommendations, using 6 mM 20 nt unmodiﬁed oligo
[Integrated DNA Technologies (IDT)] and 70 ng/mlo f
pRPC179 DNA. Reactions were stopped by chilling on ice
for 10 min. An equal volume of 80 mM 5-acetylamino-di-b-
D-galactopyranoside (FDG) (Molecular Probes), which is
cleaved by b-galactosidase to produce ﬂuorescein, was added
to the in vitro reactions to enable measurement of the activity
of b-galactosidase (34). All reactions were done in 96-well
microtiter plates, in triplicate. Fluorescence was measured
using a CytoFluor multi-well plate reader. The inhibition
percentage for an oligo is calculated as:
inhibition % ¼
1  ð fluorescence with oligoÞ
ðfluorescence without oligoÞ
· 100%:
Western blot analysis
b-galactosidase expression levels were also measured by
western blot analysis. A total of 40% of the volume of each
in vitro reaction mixture was electrophoresed on a 10%
SDS–PAGE gel at 200 V for 45 min in a Tris–SDS buffer
(25 mM Tris, 0.19 M glysine, 1 g/l SDS). Proteins were trans-
ferred to PVDF membrane (Millipore) using a Semi-dry
Transfer Cell (BioRad) according to manufacturer’s recom-
mendations. Western analysis was performed using rabbit
anti-b-galactosidase antibody (Abcam) at 1:5000 dilution.
Bands were detected using a horseradish peroxidase-
conjugated goat anti-rabbit IgG secondary antibody and
were visualized using Kodak BioMax MR ﬁlm (Sigma).
Band intensities were quantiﬁed by ImageQuant software
(Molecular Dynamics).
Secondary structure prediction
Sfold, the software implementing the structure sampling
algorithm (35), was used to generate probable structures for
the lacZ mRNA. The typical sample size of 1000 structures
was used, which has been shown to be sufﬁcient to guarantee
statistical reproducibility (30,32). Due to the tight coupling of
prokaryotic transcription and translation, the folding of the
mRNA is considered to be a local event, and local folding
has been previously used in a structural study of bacterial
genes (36). We focused our analysis using a local folding
constraint of window width 50 nt. Under this constraint,
bases separated in the sequence by >50 nt cannot form a
pair. Alternative window widths and global folding were
also considered.
Thermodynamic parameters
The potency of an antisense oligo can be potentially affected
by the secondary structure of the target (25), the self-folding
potential of the oligo, and the stability of the oligo:target
duplex (37). We deﬁne these terms in the current context
and compute the total free energy change for modeling the
hybridization process.
DGdisruption is the energy cost for disrupting the mRNA
structure so that the binding site becomes completely open
(i.e. single-stranded). In light of the local folding nature
of prokaryotic mRNAs, we consider a local disruption
model, which assumes that the alteration of target structure
due to oligo binding is local rather than global. Speciﬁcally,
we assume that only the binding site is involved in structural
alteration. Under this assumption, DGdisruption is the energy
difference between the original mRNA structure and the
new locally altered structure. For our statistical sample of
structures, the energy of the original mRNA structure,
DGbefore, can be represented by the average energy of the
original sampled structures. The energy of the locally chan-
ged structure, DGafter, can be calculated by the average
of all of the locally altered structures. We have DGdisruption ¼
DGbefore   DGafter.
DGoligo is the self-folding energy of the antisense oligo. It
is the energy of the MFE structure calculated by the mfold
program. This term characterizes the potential of secondary
structure formation for the antisense oligo. For short oligos
of 20 nt in length, the MFE structure is a good representation
of the rather small space of probable structures. Thus, we do
not consider the sampling alternative for oligo folding to be
appreciably advantageous.
DGhybrid is the energy gain due to the hybridization at the
binding site. This parameter measures the afﬁnity between
the structure-free (i.e. completely single-stranded) antisense
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sum of the stacking energies for the antisense oligo:target
duplex (hybrid), with the penalty of an initiation energy:
DGhybrid ¼ DGinitiation þ SDGstacking‚
where DGinitiation ¼ 4.1 kcal/mol (28), and the sum is over
DNA/RNA stacking energies (38) for the oligo:target duplex.
DGtotal is the total free energy change for the thermodyn-
amic cycle of energy exchanges, as illustrated in Figure 1.
It takes into account the intramolecular secondary structures
of both the target and the antisense oligo, and the stability
of the oligo:target hybrid. Thus, DGtotal is calculated by
DGtotal ¼ DGhybrid   DGdisruption   DGoligo:
Statistical analyses
Univariate linear regression and correlation analysis. The
standard linear regression is employed for predicting anti-
sense activity by each of the parameters listed above. The
P-value measures the statistical signiﬁcance of the parameter,
and the R
2 of the regression indicates the degree of variability
in antisense activity that is attributed to the parameter. The
correlation coefﬁcient between a parameter and the antisense
activity is computed. We note that the P-value of the correla-
tion is the same as the P-value of the parameter from the stan-
dard univariate regression analysis.
Multivariate regression by forward stepwise modeling. The
R
2 value may be substantially improved through inclusion
of multiple parameters in a multivariate regression analysis.
We adapt the forward stepwise method for model selection.
At each step, a new and statistically signiﬁcant parameter
that most improves the R
2 of the current model is included
in the next regression model. This process is repeated either
until all parameters are included in the ﬁnal model, or until
none of the excluded parameters can provide an appreciable
improvement. The statistical package R (39) is used for the
statistical analyses.
RESULTS
Development of in vitro assay
Evaluation of a substantial number of computationally
designed antisense oligos requires an experimental system
that can rapidly screen for oligo efﬁciency. We reasoned
that an in vitro transcription/translation system would bypass
problems associated with oligo entry into cells, and would
provide an expression readout that directly corresponds to
the accessibility and binding of the oligo to the mRNA target.
To establish such a highly sensitive in vitro assay, we
started with a set of seven antisense oligos and three negative
control oligos. In the ﬂuorescence assay, the no-oligo control,
which should represent the maximal expression of lacZ, gave
the greatest number of ﬂuorescence units (Figure 2A). The
values in ﬂuorescence units for the three negative control
oligos were close to the value of the no-oligo control. All
but one of the antisense oligos caused the number of ﬂuores-
cence units to be reduced by about half, relative to the
negative control oligos. The remaining antisense oligo,
KM726, reduced the number of ﬂuorescence units to 3% of
the no-oligo control level, which indicated that the expression
of lacZ, and consequently the activity of b-galactosidase,
were almost completely inhibited by this oligo.
The same reactions were next analyzed by Western blot
using anti-b-galactosidase antibodies, a technique which
more directly measures the amount of b-galactosidase protein
produced in each reaction. The trend of the intensities of the
b-galactosidase-speciﬁc bands produced in the presence of
various oligos was very similar to what we observed for the
results for the ﬂuorescence units (Figure 2A and B). This
agreement indicates that b-galactosidase activity assayed by
FDG corresponds well with the actual amount of the protein
in the reaction. Fluorescence units and the intensity of the
western bands were both converted to inhibition percentages,
with the no-oligo control used as the baseline (Figure 2C).
The levels of inhibition calculated from the two assays
Figure 1. Thermodynamic cycle of free energy exchanges. DGdisruption is the target disruption energy, which measures the free energy cost to open the secondary
structure at the target site; DGoligo is the self-folding minimal free energy (MFE) of the antisense oligo; DGhybrid is the binding energy (stability) for the hybrid
formed between the antisense oligo and the target site.
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assay is reliable as a fast, alternative measure of relative
b-galactosidase expression levels in this in vitro system.
Having established a reliable in vitro assay system, we then
used the ﬂuorescence-based in vitro b-galactosidase assay
system to test a total of 38 oligos. In each experiment using
standard reaction conditions, every oligo was tested with
triplicate samples, and the average inhibition percentage
was computed. Furthermore, the experiment for each oligo
was repeated independently at least twice, on different dates.
Statistical analysis of a training oligo set
A training dataset of 18 antisense oligos for the E.coli lacZ
mRNA (Table 1) was tested and analyzed. Six of the seven
oligos in Figure 2, with the exception of KM1113, were
included in the training dataset and were further tested. By
univariate regression analysis, we found a signiﬁcant correla-
tion (at the 0.05 signiﬁcance level) between DGdisruption and
antisense activity (Table 2). The correlation for DGtotal is
marginally signiﬁcant (but insigniﬁcant at the 0.05 level).
There is a lack of correlation for either DGoligo or DGhybrid.
These ﬁndings indicate that the signiﬁcance of DGtotal
was due to the DGdisruption term in the calculation of DGtotal
(see Materials and Methods). Thus, not surprisingly, multi-
variate stepwise regression did not result in a model with
improved R
2. For DGdisruption, a lack of signiﬁcant correlation
was observed when we used larger folding windows, e.g. with
width of 75 nt (P-value of 0.31), 100 nt (P-value of 0.18), or
500 nt (P-value of 0.16). For the global folding option (i.e.
with window width set equal to the length of the complete
target sequence), the P-value was 0.32. These ﬁndings further
support the choice of a window width of 50 nt for local fold-
ing of prokaryotic mRNAs. Among 10 sequence motifs that
have been reported to be signiﬁcantly correlated with
antisense activity (18), the AAA motif is present in seven
of the 18 training oligos, but was not signiﬁcantly correlated
with antisense activity (P-value of 0.39). None of the remain-
ing nine motifs appeared in more than 3 oligos; we con-
sidered such low frequency of occurrence insufﬁcient for
analysis. Based on the results of the training oligos, our
validation focuses on direct testing of an antisense design
that utilizes DGdisruption.
A structure-based antisense design and validation
We ﬁrst adapt two established empirical rules for antisense
design. These include balanced base composition (40), and
avoidance of four contiguous guanosine (G) residues which
may cause potential non-speciﬁc effects by interacting with
heparin-binding proteins (41). It is possible that the accessi-
bility for some regions of the target mRNA is heavily inﬂu-
enced by tertiary folding of the target and by binding of
proteins. Efﬁcient modeling for RNA:protein interaction is
Figure 2. Expression of b-galactosidase was quantified by both a FDG fluorescence assay and Western blot analysis. (A) Values in fluorescence units are shown
for each reaction either with or without oligo, as specified. ‘No oligo’ was the control reaction without oligo. KM726, KM728, KM729, KM730, KM1111,
KM1112 and KM1113 were designed antisense oligos. KM1002 and KM1004 were random negative controls. KM1007 was a scramble control of KM729.
Results shown represent means of triplicate samples from one experiment. Every oligo was tested independently at least three times. Error bars show standard
errors for multiple runs of the experiment. (B) Quantification of the Western blot. A total of 40% of the volume of each reaction was analyzed by Western blot.
The vertical axis shows the relative intensity of each b-galactosidase protein band from the Western blot as quantified by ImageQuant 5.1 software. (C) Inhibition
percentages for results in A (fluorescence) and in B (Western blot) are shown along with the corresponding protein bands from the Western blot. KM1008 was a
mismatch control of KM726, which was tested in the fluorescence assay but not in the Western blot. The upper protein bands represent the b-galactosidase
detected by chemiluminescence. The lower protein bands are from the Coomassie stained SDS–PAGE gel used for the Western blot assay, and serve as a uniform
loading control.
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of an RNA-binding protein is known. To avoid potential
regional bias due to these effects, we distributed oligos across
the length of the mRNA sequence. Our structure-based design
starts with implementation of the empirical rules as design
ﬁlters:
(i) For all possible target sites (here 20 nt in width) on lacZ
mRNA, we remove sites with GC content below 40% or
above 65%.
(ii) For the remaining sites from (1), we remove those that
have four or more consecutive G’s.
(iii) Sort the remaining sites from (2) by DGdisruption value,
and select sites that have the most favorable DGdisruption
values and are distributed evenly across the mRNA
sequence.
For a test set of accessible sites, we selected 10 sites by the
above design procedure. For the second test set of inaccessi-
ble sites, after steps (1) and (2) of the above design process,
we selected 10 sites that have the most unfavorable
DGdisruption values and are distributed evenly across the
mRNA sequence. These two test sets of oligos (Tables 3–5)
were tested under the same conditions and analyzed in the
same way as for the antisense oligos of the training dataset.
For the 20 antisense oligos combined from the two test sets,
the DGdisruption parameter was again found to be signiﬁcantly
correlated with the antisense activity, with a P-value
0.00753 and a regression R
2 of 0.335 (Table 6). The correla-
tion of DGtotal was slightly less signiﬁcant, and neither
DGoligo nor DGhybrid showed a signiﬁcant correlation. Thus,
the pattern of signiﬁcance parallels that for the training set,
and also that for the combination of the training set and the
two test sets (Table 7). Seven of the 10 oligos for accessible
sites were found to be effective (>50% inhibition), but none
of the oligos for inaccessible sites was effective. The aver-
age inhibition percentage was 56.0% for the accessible set,
and 38.6% for the inaccessible set. The difference between
the two sets, 17.4%, was statistically signiﬁcant with a P-
value 0.00502. These results further support the importance
of effect of target secondary structure on antisense activity
and validate the structure-based antisense design.
Greatly improved predictability of antisense activity
for oligos with target sites upstream of the end
of the active domain for b-galactosidase
We were interested in possible localization effects with
respect to the active domain of b-galactosidase. This protein
of 1023 amino acids folds into ﬁve sequential domains, with
an a-complementation region at the amino terminus (42). The
third domain contains the catalytic site, including the four
residues Glu 461, Met 502, Tyr 503 and Glu 537 that are
catalytically important (43–45).
Six oligos of the accessible test set and eight oligos of the
inaccessible test set have target sites located upstream of the
end of the active domain. For these 14 oligos, the predictabil-
ity of the antisense activity by DGdisruption improved greatly,
with a P-value of 0.000168, and R
2 of 0.706 (Table 8,
Figures 3 and 4). For both the training set and the two test
sets, there are 27 oligos that have target sites located within
the ﬁrst three domains. A substantial improvement was also
observed for these 27 oligos (Table 9, Figure 5).
It should be emphasized that antisense activity in this study
was monitored through b-galactosidase activity. It has been
Table 1. Antisense oligos of the training set
Oligo name Target site
position
Target sequence
(50!30)
Inhibition (%) Disruption energy
(kcal/mol)
No. of test
runs*
KM726 277–296 AAACCCUGGCGUUACCCAAC 89.7 ± 11.8  7.075 19
KM1227 243–262 CACUGGCCGUCGUUUUACAA 59.1 ± 9.4  13.727 4
KM1228 306–325 UUGCAGCACAUCCCCCUUUC 59.8 ± 10.5  7.009 4
KM728 733–752 UGAAUUUGACCUGAGCGCAU 40.1 ± 15.6  10.3 12
KM729 836–855 CGGAUGAGCGGCAUUUUCCG 48.9 ± 14.4  14.065 10
KM730 1133–1152 GCCGAAAUCCCGAAUCUCUA 50.4 ± 12.4  8.065 8
KM731 1357–1376 GCUGAUGAAGCAGAACAACU 27.0 ± 17.1  9.892 3
KM734 2399–2418 AACCUCAGUGUGACGCUCCC 37.0 ± 9.2  7.495 3
KM1110 514–533 UGCGCCCAUCUACACCAACG 39.4 ± 11.5  5.045 3
KM1111 1468–1487 UAUUGAAACCCACGGCAUGG 53.4 ± 11.9  8.721 8
KM1112 2262–2281 UGAUUGAACUGCCUGAACUA 58.8 ± 14.4  5.226 8
KM1165 2928–2947 GGCCGCAAGAAAACUAUCCC 66.8 ± 7.8  11.258 2
KM1159 322–341 UUUCGCCAGCUGGCGUAAUA 59.8 ± 4.2  6.953 2
KM1160 674–693 UUUCAUCUGUGGUGCAACGG 60.2 ± 10.1  5.461 2
KM1161 1299–1318 AGCAUCAUCCUCUGCAUGGU 39.8 ± 18.5  21.914 4
KM1162 1818–1837 GCCCGCUGAUCCUUUGCGAA 53.4 ± 12.5  9.671 4
KM1163 2793–2812 ACCGGAUUGAUGGUAGUGGU 23.1 ± 20.7  23.258 5
KM1164 2818–2837 GGCGAUUACCGUUGAUGUUG 39.8 ± 15.0  15.113 4
*Number of independent tests performed. Each run of the test was done with triplicate samples. For KM726, KM728, KM729, KM730, KM111 and KM1112,
inhibition data here include early runs presented in Figure 1 and additional runs after the Western blot analysis. For each run, an average inhibition percentage was
computed for the triplicate samples. The standard error was calculated using data from multiple runs.
Table 2. Correlation and univariate regression analyses for the training
dataset*
Parameter Correlation
coefficient
P-value R
2
DGoligo  0.08306 0.743156 0.0069
DGdisruption 0.474247 0.046766 0.224911
DGhybrid  0.03135 0.901733 0.000983
DGtotal  0.42346 0.079929 0.17932
*For standard univariate regression analysis, the P-value for a predictor is the
same as that for the correlation coefficient.
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fold into the correct conformation (46). An antisense oligo
targeted to the fourth or the ﬁfth domain could still give
rise to a functional b-galactosidase that may lack one or
Table 3. Test set 1 of antisense oligos with predicted accessible target sites
Oligo name Target site
position
Target sequence
(50!30)
Inhibition % Disruption energy
(kcal/mol)
No. of test
runs
KM1425 369–388 CCCAACAGUUGCGCAGCCUG 63.1 ± 4.5  2.79 2
KM1426 1007–1026 UGGCAGGGUGAAACGCAGGU 68.9 ± 5.1  7.61 2
KM1427 1671–1690 GCCCGGUGCAGUAUGAAGGC 46.9 ± 5.7  7.62 2
KM1428 1838–1857 UACGCCCACGCGAUGGGUAA 56.4 ± 4.8  6.31 2
KM1429 1959–1978 AUGAUGAAAACGGCAACCCG 70.7 ± 10.3  3.08 2
KM1430 2083–2102 AGCAAAACACCAGCAGCAGU 62.2 ± 18.2  3.79 3
KM1431 2173–2192 CGAGCUCCUGCACUGGAUGG 24.2 ± 13.9  3.00 2
KM1432 2332–2351 ACCGAACGCGACCGCAUGGU 68.8 ± 13.8  7.09 3
KM1433 2548–2567 ACAACUGCUGACGCCGCUGC 43.2 ± 3.8  7.67 2
KM1434 2839–2858 AGUGGCGAGCGAUACACCGC 55.6 ± 10.2  7.01 2
Table 4. Test set 2 of antisense oligos with predicted inaccessible target sites
Oligo name Target site
position
Target sequence
(50!30)
Inhibition % Disruption energy
(kcal/mol)
No. of test
runs
KM1435 403–422 CUUUGCCUGGUUUCCGGCAC 43.2 ± 14.1  35.19 2
KM1436 856–875 UGACGUCUCGUUGCUGCAUA 37.0 ± 11.6  21.23 2
KM1437 959–978 CAGAUGUGCGGCGAGUUGCG 37.4 ± 5.5  27.73 2
KM1438 1232–1251 CGGAUUGAAAAUGGUCUGCU 42.9 ± 7.0  22.53 2
KM1739 1329–1348 AUGAGCAGACGAUGGUGCAG 39.8 ±17.7  26.52 2
KM1440 1438–1457 CUACGGCCUGUAUGUGGUGG 30.4 ± 26.3  29.23 3
KM1441 1562–1581 CGCGAUCGUAAUCACCCGAG 22.6 ± 18.0  26.56 3
KM1442 2012–2031 CCGAACGAUCGCCAGUUCUG 35.5 ± 14.4  23.35 2
KM1443 3122–3141 CAACUGAUGGAAACCAGCCA 49.5 ± 3.0  26.88 2
KM1444 3174–3193 GGCUGAAUAUCGACGGUUUC 47.6 ± 36.7  27.59 3
Table 5. Non-overlapping of target sites for two test sets of oligos
Oligo set Separation (in nucleotide) between
adjacent sites
Mean Min Max Median
Test set 1 254 70 644 147
Test set 2 287 32 1090 104
Test sets 1 and 2 combined 127 14 433 89
Table 6. Correlation and univariate regression analyses for 20 test sites
Parameter Correlation
coefficient
P-value R
2
DGoligo  0.10046 0.673456 0.010092
DGdisruption 0.578547 0.007531 0.334716
DGhybrid  0.37592 0.102366 0.141318
DGtotal  0.57389 0.008148 0.329346
Table7. Correlation and univariate regression analyses for 20 test sites and 18
training sites
Parameter Correlation
coefficient
P-value R
2
DGoligo  0.07624 0.649164 0.005812
DGdisruption 0.512524 0.001002 0.262681
DGhybrid  0.14917 0.371408 0.022251
DGtotal  0.49575 0.001551 0.245765
Table 8. Correlation and univariate regression analyses for 14 oligos from
test sets 1 and 2 having target sites within the first three domains of
b-galactosidase
Parameter Correlation
coefficient
P-value R
2
DGoligo  0.07688 0.793931 0.00591
DGdisruption 0.840307 0.000168 0.706116
DGhybrid  0.47544 0.085761 0.22604
DGtotal  0.83233 0.000221 0.692768
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Figure 3. Linear regression for prediction of the antisense activity (shown as
inhibition % on the vertical axis) by DGdisruption for 14 oligos in the test sets
that have target sites located upstream of the end of the active domain
of b-galactosidase. The R
2 for the regression is 0.706, and the P-value for
DGdisruption is 0.000168.
Nucleic Acids Research, 2006, Vol. 34, No. 19 5665both of the ending domains due to possible translation stop-
page or target cleavage, as long as the third domain
is intact and correctly folded. Since the third domain contains
the active site, a partially synthesized b-galactosidase with
this domain corrected folded can still retain its functionality
and exhibit a negative antisense effect. Due to the
limited understanding of protein folding, it is extremely
difﬁcult, if not impossible, to determine whether or not a par-
tial b-galactosidase protein sequence can form the active
conformation and perform its physiological functions. This
uncertainty negatively affects the predictability of antisense
activity at the protein level when the active domain is not
known, and might explain why the predictive power of
our method increases dramatically when the target sites
downstream of the active domain were excluded in the
analysis.
Computational costs and software availability
The CPU times and memory requirements for our
implementation of partition function calculation and for the
sampling of 1000 structures have been previously reported
(47). The calculation of DGdisruption for each individual site is
a linear operation. However, the calculation for all possible
sites on a target mRNA becomes time-consuming. Thus,
simple design ﬁlters including GC content are used to make
computation by a web server manageable. The tools for
implementing the structure-based design are available
through the application module Soligo of the Sfold software
for the folding and design of nucleic acids. Sfold is available
through our Web server at http://sfold.wadsworth.org. Sample
output for a folded sequence is available at http://sfold.
wadsworth.org/demo.
DISCUSSION
Cell-free assay for antisense screening
The novel oligo assay system developed for this study has
several advantages over common oligo screening strategies
that are based on modiﬁed oligos, such as phosphorothioate
oligos, morpholino oligos, or locked nucleic acid oligos.
Vehicles for delivering such modiﬁed oligos into living
cells include cationic lipids, liposomes, and peptide conjuga-
tion. Effects of the antisense oligos are usually monitored by
Western blot analysis for protein expression, Northern blot
analysis or RT PCR for mRNA expression, or the measure-
ment of a speciﬁc phenotype associated with the expression
of a target gene. The interpretation of data for these screening
strategies can be complicated by the uncertainties associated
with the experimental processes. The use of cell-free extracts
is advantageous, because this allows addition of oligos
directly to the reaction mixture and avoids problems associ-
ated with penetration of oligos through the cell membrane
into the cytoplasm. Thus, the potency of an oligo is not affec-
ted by the permeability of the speciﬁc type of the oligo. Fur-
ther, since oligos are present prior to mRNA synthesis and
have ready access to the mRNA during transcription, back-
ground expression of the target gene prior to oligo addition
is avoided. This represents an improvement over other
assay systems in which the expression of the target before
entry of oligos complicates the analysis. In addition, available
Figure 4. Five sequential domains I, II, III (active domain), IV, and V of b-galactosidase (PDB ID: 1DP0), with starting residue positions given (42). For each of
the oligos in the two test sets, either a ‘+’ indicating agreement between prediction and observed inhibition, or a ‘ ’ for disagreement is placed under the protein
residue position corresponding to the target site on the lacZ mRNA. Here, prediction and observed inhibition are considered to be in agreement if either the oligo
has the observed activity >50% and its DGdisruption >  7 kcal/mol, or else the oligo has the observed activity < 50% and its DGdisruption <  20 kcal/mol. For the
20 oligos in the two test sets, agreement is observed for 12 of the 14 oligos (86%) targeted to domains I, II and III. In contrast, agreement is only observed for two
of the six oligos (33%) targeted to domains IV and V.
Table 9. Correlation and univariate regression analyses for 27 oligos from
both the training and the test sets having target sites within the first three
domains of b-galactosidase
Parameter Correlation
coefficient
P-value R
2
DGoligo  0.11058 0.582935 0.012229
DGdisruption 0.651955 0.000229 0.425045
DGhybrid  0.21194 0.288565 0.044918
DGtotal  0.64089 0.000316 0.410745
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Figure 5. Linear regression for prediction of the antisense activity (shown as
inhibition % on the vertical axis) by DGdisruption for 27 oligos in the training
set and the two test sets that have target sites located upstream of the end of
the active domain of b-galactosidase. The R
2 for the regression is 0.425, and
the P-value for DGdisruption is 0.000229.
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in our cell-free system, thereby reducing non-speciﬁc binding
of oligos to other messages normally present in whole
cells.
We observed consistent results with unmodiﬁed oligos in
our cell-free assay, but we cannot rule out the possibility of
oligo degradation in the reaction. Improved stability of oligos
may increase the potency of antisense inhibition. The use of
unmodiﬁed antisense oligos appears to contribute to the
moderate level of activity for some of the tested oligos. It
is well understood that unmodiﬁed oligos are susceptible to
DNase degradation, which lowers their effective concentra-
tion and compromises activity. Indeed, phosphorothioate
modiﬁcation of several of the most potent antisense oligos
from the test dataset led to signiﬁcant improvement (pre-
liminary data not shown). Thus, modiﬁed oligos will be
considered for future in vivo experiments. We also tested
non-speciﬁc effects often associated with high oligo concen-
trations. We found that the use of a concentration of 10 mMo f
negative control oligos increased the non-speciﬁc effects to
unacceptable levels (data not shown).
The ﬂuorescence-based assay of b-galactosidase activity
was shown to be as reliable as Western blot analysis in
these studies, and it is faster and much more amenable to
high-throughput applications. The FDG assay takes 2 h and
requires few manipulations, beyond set-up of the initial
expression reactions. In contrast, Western analysis takes a
full day, an entails many manipulations. Our ﬂuorescence-
based assay uses a 96-well-plate, which allowed us to
routinely assay 31 oligos with a no-oligo control in triplicate,
in 5 h. Thus, our ﬂuorescence-based cell-free assay allows
rapid and efﬁcient screening of many antisense candidates
to identify the best inhibitors. lacZ is an attractive target for
initial testing, because it is characterized. The  3 kb length
of its mRNA provides ample opportunities for identiﬁcation
of potent target sites. This lacZ reporter system can also be
easily adapted for screening oligos against other targets.
Structure-based antisense design
In this work, we have computed energetic parameters for
modeling oligo:target hybridization. In particular, the cal-
culation of the target disruption energy DGdisruption takes
advantage of our structure sampling algorithm that has been
shown to effectively represent the likely population of
mRNA structures, thus overcoming limited representation
by the optimal folding or a heuristic set of suboptimal
foldings for antisense target prediction. As a measure of
target structural accessibility, DGdisruption was found to be
the most important predictor for antisense activity. This ﬁnd-
ing is in agreement with previous reports based on experi-
mental methods (15,25) or alternative computational
approaches (21,22,48).
In our study, we selected non-overlapping test sites that are
distributed evenly across the sequence of the target mRNA.
This strategy not only avoids potential auto-correlation
among overlapped sites which could introduce a bias for
data analysis, but also ensures the independence of the sites,
which is an implicit assumption for valid regression analysis.
In a previous study, the oligo binding energy DGhybrid was
found to be correlated with antisense activity (37).
Such a correlation was not found in our study. It is possible
that the contradictory results are partly due to overlapping of
some target sites in the previous study. However, the raw data
in that study were not made available to enable us to assess
the extent of overlap.
It has been shown that the secondary structure of
antisense RNAs of  100 nt is important for the kinetics of
the antisense activity (49). In our study, the stability of
20 nt antisense oligo was not correlated with antisense activ-
ity. This suggests that, for short oligos, the effect of oligo
folding is too small to have a signiﬁcant impact on antisense
binding.
The window width of 50 nt was used by Sfold for local
folding of lacZ mRNA. The signiﬁcance of DGdisruption dimin-
ished for larger folding windows. This ﬁnding suggests that in
prokaryotes, where transcription and translation are tightly
coupled so that the mRNA is bound by multiple translational
machineries, the folding of mRNA is likely constrained
within local regions. Our observation is consistent with the
local folding consideration in a structure study on bacterial
mRNAs (36).
The proposed design method assumes that oligo:target
hybridization causes only local disruption of the target struc-
ture. In view of the local nature of the folding of prokaryotic
mRNAs, we consider the local disruption model to be a
reasonable approximation for prokaryotic applications. For
eukaryotes, mature mRNAs are transported from the nucleus
into the cytoplasm where translation occurs and where
regulatory mechanisms are present. Thus, the folding of a
eukaryotic mRNA may be global. For eukaryotic applica-
tions, the alternative to the local disruption model is the
global disruption model, which assumes that the binding of
an oligo induces global alteration of target structure. This
global model has been considered previously for modeling
of antisense binding based on MFE predictions (22,48).
The application of our structure sampling in this context
will require re-folding of the target, with the binding site
constrained to be unpaired, so as to generate a new sample
of probable mRNA structures. The modiﬁed computing
method will need to be tested in a eukaryotic system.
The combination of the computational design and the
rapid cell-free assay renders our method applicable to high-
throughput antisense applications. The lacZ system can be
extended by gene fusion approaches (50,51). Thus, the
approach we have outlined can be adapted for use with any
gene of interest, and should be especially useful for
functional screening of genes, and for identiﬁcation of new
drug targets in pathogenic microbes. We are currently devel-
oping functional genomics applications for Mycobacterium
tuberculosis and Yersinia pestis.
The goal of an antisense experiment is to down-regulate
the expression of the target protein. For the multiple-domain
enzyme b-galactosidase, a partly synthesized peptide (in the
case of successful antisense binding and target cleavage)
has the potential to fold correctly (46) and behaves function-
ally as an intact protein. Thus, to maximize the degree of
correspondence between antisense binding and the protein
expression in bacterial functional genomics applications of
the lacZ reporter, it is advisable to select target sites upstream
of the end of the known active domain of the target protein.
As indicated by the results for b-galactosidase, the antisense
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active domain. For these sites, data interpretation is further
complicated by our currently limited understanding of protein
folding. We emphasize that the ﬁnding of the regional effects
with respect to the active domain of the target protein is based
on one system tested for one target. Generalization of this
ﬁnding will require large scale testing of other targets with
known active domains.
The concentration of the target is relevant for bi-molecular
interaction, but is unknown and thus is difﬁcult to take into
account in equilibrium equations of reactions. Also, it is
unknown whether the target concentration in the cell-free
system is comparable to that in an in vivo system. Clearly,
the ratio of the oligo concentration and the target concentra-
tion is important. For the same oligo concentration, it is
difﬁcult to assess whether the above ratio for the cell-free
system is comparable to that for an in vivo system. In the
cell-free system, the oligos have ready access to the target,
whereas inefﬁcient uptake across the cell wall is expected
to be an issue for an in vivo bacterial system (52). Thus,
the effective oligo concentration for the cell-free system is
expected to be higher than that for an in vivo system. In
this case, the equilibrium between unbound oligo and
unbound target, and oligo:target hybrid, may be shifted
toward oligo:target hybridization, effectively reducing the
effect of the target structure. In other words, for the same
oligo concentration, the effect of target structure may be
greater for an in vivo system in comparison to our cell-free
system. Clearly, the effects of target structure and other
parameters studied here need to be re-examined in an
in vivo system. This will require large scale in vivo testing.
The target sites of all tested oligos are down stream from
the translation initiation site. The initiation codon AUG starts
at nucleotide position 74 of the lacZ mRNA, whereas the
target site closest to AUG (oligo KM1227), starts at nucleo-
tide position 243. Thus, blockage of the translation initiation
complex (53) is unlikely to be the antisense mechanism for
the oligos described in this study. Either translation arrest
through blockage of the translational machinery, or RNAse
associated RNA degradation, or both, are more likely mecha-
nisms. RNase H, the ribonuclease that speciﬁcally degrades
the RNA strand of DNA:RNA hybrid, is expected to be
present in the cell extracts (Promega). More generally, mem-
bers of RNase H family can be found in nearly all organisms
including prokaryotes.
In a study of hybridization experiments with large numbers
of oligo probes, oligo self-folding and the stability of the oli-
go:target hybrid, i.e. the DGhybrid here, were found to be
signiﬁcantly correlated with the hybridization intensity (54).
Similar ﬁndings were reported for a large number of antisense
experiments in eukaryotic systems (37). We could not
conﬁrm these ﬁndings in our test system. Our study measured
prokaryotic gene expression rather than intensity of hybrid-
ization between interacting nucleic acids, or eukaryotic
gene expression. In addition to these fundamental differences,
for the oligos tested in our study, the GC content ranges from
40 to 65%, with an average of 55%. It is possible that the
balanced GC content in our study does not provide sufﬁcient
variation in the stability of the oligo or the oligo:target duplex
to allow for detection of correlation. The target structure was
not considered in the analysis of probing data. For the other
study, a heuristic set of suboptimal structures was used,
but no correlation between target structure and antisense
activity was found. The disruption energy based on a statisti-
cal sample of structures generated by global folding
presents a novel tool for an alternative structural analysis of
these data.
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